6533b85efe1ef96bd12bf467
RESEARCH PRODUCT
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Christoph KleinschnitzBoris KallmannFrank WeberFlorian DeisenhammerHayrettin TumaniMichael PlattenLuisa KlotzFedor HeidenreichKarl BaumUwe K. ZettlTjalf ZiemssenRalf A. LinkerH. WiendlStephan SchmidtSven G. MeuthChristian EnzingerStefan BittnerElisabeth FertlVerena I. LeussinkVolker LimmrothRenaud Du PasquierFranziska Di PauliMichael GugerMartin BerghoffUta Meyding-lamadéAchim GassAdam CzaplinskiHans-peter HartungPeter RieckmannNorbert GoebelsKlaus GehringAiden HaghikiaOlaf HoffmannMathias MäurerTobias DerfussFrauke ZippThomas BergerFritz LeutmezerMartin S. WeberOrhan AktasRalf GoldJan D. LünemannAndreas LutterottiAndrew T. ChanClaudio Gobbisubject
Position statementmedicine.medical_specialtytreatment recommendationMedizin610 Medicine & healthReviewDiseasemultiple sclerosis03 medical and health sciences0302 clinical medicineWhite paperNeuronal damagemedicine030212 general & internal medicineRC346-429610 Medicine & healthIntensive care medicinePharmacologybusiness.industryMultiple sclerosisDisease mechanismsGuidelinemedicine.diseasedisease-modifying therapy3. Good healthGroup treatmentNeurologyNeurology. Diseases of the nervous systemNeurology (clinical)businessguideline030217 neurology & neurosurgerydescription
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland). in press, CA extern
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-08-01 | Therapeutic Advances in Neurological Disorders |